Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SPAG9_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SPAG9_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SPAG9_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/SPAG9_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SPAG9_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SPAG9_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SPAG9_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SPAG9_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SPAG9_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SPAG9_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00511461 | Lung | AIS | striated muscle cell differentiation | 42/1849 | 283/18723 | 4.88e-03 | 4.24e-02 | 42 |
GO:002260432 | Lung | MIAC | regulation of cell morphogenesis | 38/967 | 309/18723 | 6.47e-07 | 9.76e-05 | 38 |
GO:00426922 | Lung | MIAC | muscle cell differentiation | 39/967 | 384/18723 | 4.51e-05 | 2.36e-03 | 39 |
GO:006056021 | Lung | MIAC | developmental growth involved in morphogenesis | 26/967 | 234/18723 | 1.99e-04 | 7.15e-03 | 26 |
GO:199013821 | Lung | MIAC | neuron projection extension | 21/967 | 172/18723 | 2.21e-04 | 7.66e-03 | 21 |
GO:001648222 | Lung | MIAC | cytosolic transport | 20/967 | 168/18723 | 4.31e-04 | 1.23e-02 | 20 |
GO:004858821 | Lung | MIAC | developmental cell growth | 25/967 | 234/18723 | 4.75e-04 | 1.29e-02 | 25 |
GO:001604922 | Lung | MIAC | cell growth | 42/967 | 482/18723 | 6.66e-04 | 1.59e-02 | 42 |
GO:004593632 | Lung | MIAC | negative regulation of phosphate metabolic process | 38/967 | 441/18723 | 1.44e-03 | 2.54e-02 | 38 |
GO:001056332 | Lung | MIAC | negative regulation of phosphorus metabolic process | 38/967 | 442/18723 | 1.50e-03 | 2.60e-02 | 38 |
GO:004863821 | Lung | MIAC | regulation of developmental growth | 30/967 | 330/18723 | 1.96e-03 | 3.12e-02 | 30 |
GO:1903859 | Lung | MIAC | regulation of dendrite extension | 6/967 | 27/18723 | 2.17e-03 | 3.35e-02 | 6 |
GO:0097484 | Lung | MIAC | dendrite extension | 7/967 | 37/18723 | 2.53e-03 | 3.62e-02 | 7 |
GO:004232632 | Lung | MIAC | negative regulation of phosphorylation | 33/967 | 385/18723 | 3.11e-03 | 4.17e-02 | 33 |
GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
GO:001056320 | Oral cavity | OSCC | negative regulation of phosphorus metabolic process | 246/7305 | 442/18723 | 6.12e-13 | 2.89e-11 | 246 |
GO:004593620 | Oral cavity | OSCC | negative regulation of phosphate metabolic process | 245/7305 | 441/18723 | 8.85e-13 | 4.09e-11 | 245 |
GO:00161979 | Oral cavity | OSCC | endosomal transport | 141/7305 | 230/18723 | 5.40e-12 | 2.06e-10 | 141 |
GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
GO:004232619 | Oral cavity | OSCC | negative regulation of phosphorylation | 214/7305 | 385/18723 | 2.30e-11 | 7.74e-10 | 214 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPAG9 | SNV | Missense_Mutation | | c.2055N>A | p.Met685Ile | p.M685I | O60271 | protein_coding | deleterious(0) | possibly_damaging(0.829) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SPAG9 | SNV | Missense_Mutation | | c.1695N>G | p.Asn565Lys | p.N565K | O60271 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SPAG9 | SNV | Missense_Mutation | novel | c.1054N>A | p.Asp352Asn | p.D352N | O60271 | protein_coding | deleterious(0) | benign(0.153) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SPAG9 | SNV | Missense_Mutation | | c.1414N>C | p.Glu472Gln | p.E472Q | O60271 | protein_coding | tolerated(0.11) | probably_damaging(0.986) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPAG9 | SNV | Missense_Mutation | | c.1126N>C | p.Asp376His | p.D376H | O60271 | protein_coding | deleterious(0.04) | benign(0.365) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
SPAG9 | SNV | Missense_Mutation | novel | c.2686N>A | p.Glu896Lys | p.E896K | O60271 | protein_coding | deleterious(0.03) | benign(0.157) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
SPAG9 | SNV | Missense_Mutation | rs764197165 | c.2489N>G | p.Asn830Ser | p.N830S | O60271 | protein_coding | tolerated(0.77) | benign(0.001) | TCGA-E2-A1IH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
SPAG9 | SNV | Missense_Mutation | | c.459N>C | p.Lys153Asn | p.K153N | O60271 | protein_coding | deleterious(0) | possibly_damaging(0.816) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SPAG9 | SNV | Missense_Mutation | | c.202G>A | p.Asp68Asn | p.D68N | O60271 | protein_coding | tolerated(1) | benign(0) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
SPAG9 | SNV | Missense_Mutation | novel | c.127G>A | p.Asp43Asn | p.D43N | O60271 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-LL-A5YP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |